Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242697 | 0.86 | KDM4E (0.61) | KDM4EALOX15PKMDYRK1AGAA | |
| SCHEMBL11825406 | 0.85 | KDM4E (0.47) | KDM4EALOX15PKMMAPTMAPK1 | |
| SCHEMBL244184 | 0.85 | KDM4E (0.66) | KDM4EALOX15PKMGAAMAPT | |
| SCHEMBL13696639 | 0.84 | KDM4E (0.59) | KDM4EALOX15PKMDYRK1AGAA | |
| SCHEMBL14590419 | 0.83 | MAPT (0.59) | KDM4EALOX15PKMGAAMAPT | |
| SCHEMBL1012134 | 0.83 | KDM4E (0.58) | KDM4EALOX15PKMDYRK1AGAA | |
| SCHEMBL12929380 | 0.83 | KDM4E (0.61) | KDM4EALOX15PKMDYRK1AGAA | |
| SCHEMBL1014816 | 0.82 | KDM4E (0.57) | KDM4EALOX15PKMDYRK1AGAA | |
| SCHEMBL8267775 | 0.82 | PKM (0.52) | KDM4EALOX15PKMDYRK1AGAA | |
| SCHEMBL25257072 | 0.81 | POLB (0.51) | KDM4EALOX15PKMGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1682532-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | Warner-Lambert Company LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042519-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K) | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-3975384-A | ANTITHROMBOTICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | KDM4E 1727/4885ALOX15 242/4885PKM 2041/4885 |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KDM4E 1400/4885ALOX15 157/4885PKM 3030/4885 |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | PIK3CA, PIK3CD, PIK3R5 | KDM4E 2264/4885ALOX15 1762/4885PKM 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.